To include your compound in the COVID-19 Resource Center, submit it here.

Priority Review for Novartis' Tafinlar plus Mekinist for melanoma

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted and granted Priority Review to an sNDA for Tafinlar

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE